A Phase 4 interventional study of Prevenar and Infanrix hexa in Vaccines, Pneumococcal, Infant and Fever, Chemically Induced, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 56 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-21.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer · Phase 4, Interventional, and Prevention
The purpose of the study is to determine whether prophylactic antipyretic treatment after vaccination with Prevenar and a concomitant hexavalent DTPa combination vaccine reduces the rate of febrile reactions.
601 studies on the registry are indexed under Fever; 101 are open to participants now.
This study's enrollment of 300 is above the median of 100 across 382 interventional studies indexed under Fever.
Browse Fever studies →Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 472 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Rectal temperature >= 38°C within days 1-4 post vaccination after any of the doses 1-4
Rectal temperature > 39.0°C occurring within 4 days of vaccine administration after each of the doses 1-4
No study locations are listed for this record.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyeth is now a wholly owned subsidiary of Pfizer